Clorox (CLX) Aandelenoverzicht
The Clorox Company produceert en verkoopt wereldwijd consumenten- en professionele producten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 4/6 |
CLX Community Fair Values
Create NarrativeSee what 100 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Clorox Company Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$106.69 |
| 52 Week Hoogtepunt | US$128.90 |
| 52 Week Laag | US$84.70 |
| Bèta | 0.54 |
| 1 maand verandering | 11.66% |
| 3 maanden verandering | 12.18% |
| 1 Jaar Verandering | -11.32% |
| 3 jaar verandering | -30.96% |
| 5 jaar verandering | -35.28% |
| Verandering sinds IPO | 5,863.46% |
Recent nieuws en updates
Seeking Alpha • Aug 21
Clorox: A Better Business, But Too Much Growth Is Priced In
Summary I reiterate a Hold rating on The Clorox Company, as the current valuation requires unsustainably high free cash flow growth. Recent positives include the GOJO acquisition and ERP rollout, but organic revenue growth remains limited after adjusting for these factors. CLX's balance sheet is heavily leveraged post-acquisition, constraining reinvestment and raising dividend sustainability concerns. Despite optimism around wellness trends, I see an insufficient margin of safety at current prices and recommend monitoring for a significant price drop. Read the full article on Seeking Alpha
Narratiefupdate • Aug 21
CLX: GOJO Integration And ERP Gains Will Support Long Term Earnings
The updated analyst price target for Clorox has shifted lower by about $8 per share, with analysts pointing to wider uncertainty around FY27 earnings, softer recent share trends and the potential for increased reinvestment under new leadership as key factors. Analyst Commentary Recent Street research on Clorox shows a mix of caution and optimism, with several bullish analysts lifting price targets even as others trim expectations on longer term earnings guidance.
Narratiefupdate • Aug 06
CLX: GOJO Deal And Leadership Transition Will Shape Healthcare Portfolio Outlook
Clorox's updated analyst price target has shifted slightly lower to about $101.71, reflecting analysts' mixed revisions around FY27 earnings visibility, new leadership, and a wider range of potential outcomes highlighted in recent research. Analyst Commentary Recent research on Clorox shows a tight cluster of price targets around the high US$90s to low US$100s.Recent updates
Seeking Alpha • Aug 21
Clorox: A Better Business, But Too Much Growth Is Priced In
Summary I reiterate a Hold rating on The Clorox Company, as the current valuation requires unsustainably high free cash flow growth. Recent positives include the GOJO acquisition and ERP rollout, but organic revenue growth remains limited after adjusting for these factors. CLX's balance sheet is heavily leveraged post-acquisition, constraining reinvestment and raising dividend sustainability concerns. Despite optimism around wellness trends, I see an insufficient margin of safety at current prices and recommend monitoring for a significant price drop. Read the full article on Seeking AlphaNarratiefupdate • Aug 21
CLX: GOJO Integration And ERP Gains Will Support Long Term Earnings
The updated analyst price target for Clorox has shifted lower by about $8 per share, with analysts pointing to wider uncertainty around FY27 earnings, softer recent share trends and the potential for increased reinvestment under new leadership as key factors. Analyst Commentary Recent Street research on Clorox shows a mix of caution and optimism, with several bullish analysts lifting price targets even as others trim expectations on longer term earnings guidance.Narratiefupdate • Aug 06
CLX: GOJO Deal And Leadership Transition Will Shape Healthcare Portfolio Outlook
Clorox's updated analyst price target has shifted slightly lower to about $101.71, reflecting analysts' mixed revisions around FY27 earnings visibility, new leadership, and a wider range of potential outcomes highlighted in recent research. Analyst Commentary Recent research on Clorox shows a tight cluster of price targets around the high US$90s to low US$100s.Narratiefupdate • Jul 23
CLX: GOJO Integration And Execution Improvements Will Support Long Term Earnings
For Clorox, the analyst price target has been trimmed by about $3 to reflect slightly lower modeled revenue growth and profit margins, even as recent Street research shows a mix of modest target hikes and cuts related to upcoming earnings and category trends. Analyst Commentary Recent Street research on Clorox shows a mix of trims and increases to price targets, with several bullish analysts highlighting potential for steadier execution and a more balanced risk and reward profile around upcoming earnings.
Narratiefupdate • Jul 08
CLX: Mounting Execution Risks Around GOJO Integration Will Pressure Future Earnings Power
Clorox's analyst price target has been reduced by $6 to $77, as analysts factor in slightly more cautious revenue growth assumptions, a modestly higher profit margin outlook, and a lower future P/E multiple. Analyst Commentary Recent research on Clorox reflects a clear tilt toward caution, with multiple bearish analysts trimming their price targets and one downgrade from JPMorgan adding to the negative tone.Analyse-artikel • Jun 16
Clorox (CLX) Stock Could Be 44% Below Fair Value Despite Recent Bounce
Clorox (CLX) stock has been drawing attention after recent performance figures showed mixed returns across different timeframes, prompting investors to reassess how the company’s current valuation lines up with its fundamentals and longer term track record. See our latest analysis for Clorox. At a share price of US$95.98, Clorox has seen its 30 day share price return rise 6.11%, while the 90 day share price return fell 13.84% and the 1 year total shareholder return declined 19.06%. This...Narratiefupdate • Jun 13
CLX: GOJO Integration And Healthcare Expansion Will Shape Future Portfolio Multiple
Narrative Update The analyst price target for Clorox is updated lower from $115.47 to $105.29, reflecting a series of Street revisions as analysts factor in a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Recent research on Clorox reflects a broad reset in expectations, with multiple firms trimming price targets and at least one downgrade from JPMorgan.Narratiefupdate • May 30
CLX: Execution Risks And Leadership Transition Will Constrain Future Earnings Power
Clorox's analyst fair value estimate has been revised down from $94.00 to $83.00 as analysts factor in updated assumptions around discount rates, margins, and future P/E, in light of a broad wave of recent price target cuts across the Street. Analyst Commentary Recent Street research has tilted clearly cautious on Clorox, with a series of price target cuts and at least one downgrade from JPMorgan.Narratiefupdate • May 14
CLX: GOJO Integration And Need Based Focus Will Support Long Term Earnings
Analysts have trimmed the blended fair value estimate for Clorox to about $144 from roughly $155, as a series of firms cut price targets, citing refreshed views on growth, margins, and future P/E multiples following recent research updates. Analyst Commentary Recent research has been dominated by cuts to fair value estimates and price targets, yet there are still some constructive signals in the commentary that matter if you are focused on Clorox's long term setup rather than just near term P/E compression.Narratiefupdate • Apr 29
CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple
Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.Narratiefupdate • Apr 15
CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power
Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.Narratiefupdate • Mar 31
CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power
Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.Narratiefupdate • Mar 17
CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook
Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.Narratiefupdate • Mar 03
CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power
Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.Narratiefupdate • Feb 17
CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E
The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.Narratiefupdate • Feb 03
CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple
Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.Narratiefupdate • Jan 20
CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating
Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.Narratiefupdate • Jan 05
CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating
Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.Narratiefupdate • Dec 20
CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook
Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.Narratiefupdate • Dec 05
CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery
Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.Narratiefupdate • Nov 21
CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026
Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.Analyse-artikel • Nov 12
Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet
Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...Analyse-artikel • Nov 10
Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues
The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...Narratiefupdate • Nov 06
CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026
Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.Narratiefupdate • Oct 23
Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook
Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.Narratiefupdate • Oct 09
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.Narratiefupdate • Aug 27
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.Seeking Alpha • Mar 29
Clorox: Reviving From Cyberattack; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Clorox: A Wonderful Business I Would Like To Own At A Lower Price
Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking AlphaRendement voor aandeelhouders
| CLX | US Household Products | US Markt | |
|---|---|---|---|
| 7D | 0.9% | -0.2% | -1.5% |
| 1Y | -11.3% | -8.4% | 17.8% |
Rendement versus industrie: CLX presteerde slechter dan de US Household Products -sector, die het afgelopen jaar een rendement van -8.4 % opleverde.
Rendement versus markt: CLX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 17.8 % opleverde.
Prijsvolatiliteit
| CLX volatility | |
|---|---|
| CLX Average Weekly Movement | 5.0% |
| Household Products Industry Average Movement | 4.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: CLX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van CLX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1913 | 9,200 | Linda Rendle | www.thecloroxcompany.com |
The Clorox Company produceert en verkoopt wereldwijd consumenten- en professionele producten. Het bedrijf is actief in vier segmenten: Gezondheid en Welzijn, Huishoudelijke producten, Lifestyle en Internationaal. Het bedrijf biedt reinigings- en desinfectieproducten voor thuisgebruik, wasmiddelen, huidreinigings- en -desinfectieproducten, professionele reinigings- en desinfectieproducten en professionele producten voor de horeca aan onder de merknamen Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Liquid-Plumr, Formula 409, Purell, GOJO, CloroxPro, Clorox Healthcare, Hidden Valley, Poett, Clorinda en Chux.
The Clorox Company Samenvatting
| CLX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$12.90b |
| Inkomsten(TTM) | US$587.00m |
| Inkomsten(TTM) | US$6.72b |
22.0x
Koers/Winstverhouding1.9x
P/S-verhoudingIs CLX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CLX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$6.72b |
| Kosten van inkomsten | US$3.88b |
| Brutowinst | US$2.84b |
| Overige uitgaven | US$2.26b |
| Inkomsten | US$587.00m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 4.85 |
| Brutomarge | 42.32% |
| Nettowinstmarge | 8.74% |
| Schuld/Eigen Vermogen Verhouding | 2,011.1% |
Hoe presteerde CLX op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
4.7%
Huidig dividendrendement103%
UitbetalingsratioBetaalt CLX een betrouwbaar dividend?
Zie CLX dividendgeschiedenis en benchmarks| Clorox dividenddata | |
|---|---|
| Ex Dividend Datum | Aug 12 2026 |
| Betaaldatum dividend | Aug 28 2026 |
| Dagen tot Ex-dividend | 12 days |
| Dagen tot dividendbetaaldatum | 4 days |
Betaalt CLX een betrouwbaar dividend?
Zie CLX dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/23 01:05 |
| Aandelenkoers aan het einde van de dag | 2026/08/21 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2026/06/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
The Clorox Company wordt gevolgd door 29 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| John Staszak | Argus Research Company |
| Lauren Lieberman | Barclays |
| Constance Maneaty | BMO Capital Markets Equity Research |